Effects Of Calcium Fructoborate On Levels Of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, And MCP-1: A Double-blind, Placebo-controlled Clinical Study
Notes for this study:
||Mean and SD. Placebo: before 194.5 ± 23.2, after 193 ± 20.4. Low dose: before 193.4 ± 43.1, after 180.1 ± 38.1. High dose: before 197.6 ± 33.8, after 186.7 ± 26.7.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 90 healthy participants were allocated to take placebo, 56 mg (1.5 mg of boron) or 112 mg (3 mg of boron) of calcium fructoborate, for 30 days.
Both boron groups saw comparable reductions in total cholesterol, LDL, and triglycerides that were statistically significant compared with placebo. HDL and glucose weren't notably changed. C-reactive protein, IL-1b, IL-6, MCP-1 were reduced more in the boron groups while than placebo, and statistically significant for the high dose group for all but c-reactive protein, and significant for the low dose for group for all but IL-6, and c-reactive protein. Homocysteine was reduced more in the boron groups, though it's unclear if the difference was statistically significant compared with placebo.